Atrium Therapeutics, Inc.
RNANASDAQHealthcareBiotechnology
As of Oct 23, 2026 close
- Market cap
- $140.27M
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $7.49$73.06
- Volume (live)
- -
- Avg. volume (3M)
- 321.81K
Atrium Therapeutics (RNA) Stock Price & Financial Analysis
Atrium Therapeutics Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $7.78 - $8.21 |
|---|---|
| 52-Week High | $73.06 |
| 52-Week Low | $7.49 |
| Open | $8.06 |
| Volume (last close) | 192.64K |
| Average Volume (3M) | 321.81K |
| Revenue (TTM) | 35.84M |
|---|---|
| Net Income (TTM) | -93.17M |
| Free Cash Flow (TTM) | -56.50M |
| EPS (TTM) | −$1.97 |
| Profit Margin | -260.00% |
| Operating Margin | -268.98% |
| Return on Equity (ROE) | -43.42% |
| Debt to Equity | 0.01 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Market Cap | 140.27M |
|---|---|
| Shares Outstanding | 17.11M |
| Price to Sales (P/S) | 3.91 |
| Price to Book (P/B) | 0.65 |
| EV/EBITDA | -0.73 |
| 50-Day MA | $10.51 |
|---|---|
| 200-Day MA | $23.43 |
| 1-Year Change | −83.19% |
Source: Market prices and company fundamentals. Data as of Oct 23, 2026. Data sources and methodology
Atrium Therapeutics at a Glance
As of the Oct 23, 2026 close, Atrium Therapeutics (RNA) has a market capitalization of $140.27M. The stock trades at 3.9× sales. Over the trailing twelve months it lost $93.17M on revenue of $35.84M and burned $56.50M of free cash flow. Revenue grew 235.3% year over year.
As of its latest reported balance sheet, it holds $72.33M in cash and securities against $1.68M of debt, a net cash position of $70.65M.
Atrium Therapeutics does not currently pay a dividend.
The share price is down 83.2% over the past year. At $8.20 (the Oct 23, 2026 close) it sits near the bottom of its 52-week range of $7.49 to $73.06, below its 200-day moving average of $23.43.
Frequently Asked Questions About Atrium Therapeutics
What is the current stock price for RNA?
As of the Oct 23, 2026 close, RNA stock trades at $8.20. The 52-week range is $7.49–$73.06, with a day range of $7.78–$8.21.
What is the P/E ratio for RNA?
The P/E ratio (Price-to-Earnings) for RNA is shown in the Key Statistics section. This valuation metric helps compare Atrium Therapeutics, Inc. to industry peers.
Does RNA pay dividends?
Atrium Therapeutics does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for RNA?
Analyst ratings and recommendations for RNA are displayed in the Analyst Consensus section, including buy/hold/sell distribution and 12-month price targets.
What is the market cap of RNA?
As of the Oct 23, 2026 close, Atrium Therapeutics's market capitalization is $140.3M, classifying it as a micro-cap company. Atrium Therapeutics operates in the Healthcare sector within the Biotechnology industry.